Mosaic ImmunoEngineering (OTCMKTS:CPMV – Get Free Report) and Fennec Pharmaceuticals (NASDAQ:FENC – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, earnings, valuation, profitability, analyst recommendations and dividends.
Analyst Ratings
This is a summary of recent ratings and target prices for Mosaic ImmunoEngineering and Fennec Pharmaceuticals, as reported by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Mosaic ImmunoEngineering | 0 | 0 | 0 | 0 | 0.00 |
Fennec Pharmaceuticals | 0 | 0 | 3 | 1 | 3.25 |
Fennec Pharmaceuticals has a consensus price target of $13.67, indicating a potential upside of 126.27%. Given Fennec Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts plainly believe Fennec Pharmaceuticals is more favorable than Mosaic ImmunoEngineering.
Institutional & Insider Ownership
Profitability
This table compares Mosaic ImmunoEngineering and Fennec Pharmaceuticals’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Mosaic ImmunoEngineering | N/A | N/A | -1,371.05% |
Fennec Pharmaceuticals | -2.30% | -53.38% | -2.08% |
Risk and Volatility
Mosaic ImmunoEngineering has a beta of 0.01, meaning that its share price is 99% less volatile than the S&P 500. Comparatively, Fennec Pharmaceuticals has a beta of 0.27, meaning that its share price is 73% less volatile than the S&P 500.
Valuation & Earnings
This table compares Mosaic ImmunoEngineering and Fennec Pharmaceuticals”s gross revenue, earnings per share (EPS) and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Mosaic ImmunoEngineering | N/A | N/A | -$1.01 million | ($0.15) | -6.67 |
Fennec Pharmaceuticals | $21.25 million | 7.80 | -$16.05 million | ($0.10) | -60.39 |
Mosaic ImmunoEngineering has higher earnings, but lower revenue than Fennec Pharmaceuticals. Fennec Pharmaceuticals is trading at a lower price-to-earnings ratio than Mosaic ImmunoEngineering, indicating that it is currently the more affordable of the two stocks.
Summary
Fennec Pharmaceuticals beats Mosaic ImmunoEngineering on 9 of the 14 factors compared between the two stocks.
About Mosaic ImmunoEngineering
Mosaic ImmunoEngineering, Inc., a development-stage biotechnology company, focuses on developing and commercializing immunomodulator platform technology for the treatment of cancer and infectious diseases in humans and for veterinary use. Its lead immunotherapy product candidate, MIE-101, a nanoparticle-based treatment derived from cowpea mosaic virus, which is non-infectious in humans and animals. The company was founded in 2020 and is based in Novato, California.
About Fennec Pharmaceuticals
Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.
Receive News & Ratings for Mosaic ImmunoEngineering Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mosaic ImmunoEngineering and related companies with MarketBeat.com's FREE daily email newsletter.